SCHEMBL6550207

SCHEMBL6550207

C=CCNC(=O)C1CC[C@H]2[C@@H]3CCC4NC(=O)C=C[C@]4(C)[C@@H]3CC[C@]12C

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 15/20 0.72
SRD5A2 P31213 8/20 0.72
LMNA P02545 2/20 0.72
CYP3A4 P08684 2/20 0.72
CYP2C9 P11712 2/20 0.72
CYP2C19 P33261 2/20 0.72
ABCC4 O15439 1/20 0.72
ABCB11 O95342 1/20 0.72
ADORA3 P0DMS8 1/20 0.72
CHRM1 P11229 1/20 0.72
HSD3B1 P14060 1/20 0.72
NFKB1 P19838 1/20 0.72
MAPK1 P28482 1/20 0.72
THPO P40225 1/20 0.72
BLM P54132 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6550206 1.00 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL11002514 0.89 SRD5A1 (0.75) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL11002519 0.89 SRD5A1 (0.75) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL2294377 0.87 SRD5A1 (0.78) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL9392056 0.87 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL9392062 0.87 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL2294373 0.87 SRD5A1 (0.78) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL2292660 0.87 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL29207253 0.87 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9
SCHEMBL2292655 0.87 SRD5A1 (0.72) SRD5A1SRD5A2LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1116725-B1 PROCESS FOR OBTAINING 17BETA-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS RAGACTIVES SL (ES) 2004-01-14 EP disclosed
US-6509466-B2 Reacting 17 beta-(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent RAGA CONSULTORES, S.L. (ES) 2003-01-21 US disclosed
US-20010008895-A1 Process for obtaining 17 beta-(N-tert-butylcarbamoyl)-3-one4-aza-steroids RAGA CONSULTORES, S.L. 2001-07-19 US disclosed
EP-1116725-A1 PROCESS FOR OBTAINING 17BETA-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS Raga Consultores, S.L. (ES) 2001-07-18 EP disclosed
WO-1994022900-A1 AZA-ANDROSTANE-17β-CARBOXAMIDES CIBA-GEIGY AG (CH) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008895-A1 Process for obtaining 17 beta-(N-tert-butylcarbamoyl)-3-one4-aza-steroids CYP17A1, HSD17B7, CYP51A1 SRD5A1 8/4885SRD5A2 14/4885LMNA 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.